9Y4.F RYVU THERAPEUTICS ZY-40

Healthcare Biotechnology Frankfurt Exchange
3.54 EUR
Close of Nov 11, 2026
3.11 6.98
Market cap
EUR 81.7M
P/E
-
P/B
12.68x
ROE
-181.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 9Y4.F undervalued?

Graham number

The Graham number of RYVU THERAPEUTICS ZY-40 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

RYVU THERAPEUTICS ZY-40 fundamental analysis

No fundamental analysis for RYVU THERAPEUTICS ZY-40 yet.

RYVU THERAPEUTICS ZY-40 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About RYVU THERAPEUTICS ZY-40

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company's lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kin…

Full company profile